CardioExchange Archive

October 19th, 2010

DES: Top Six Things You Should Know

CardioExchange Editors, Staff

Finding it hard to keep up with all of the new DES research? Interventional Cardiology Co-Moderator Rick Lange offers this brief tutorial on the “top six things every cardiologist should know about DES.” Would you add anything to Rick’s list? Tell us your thoughts here.

---

October 6th, 2010

The Skinny on Drug-Eluting Stents (DES)

Richard A. Lange, MD, MBA

(“All we want are the facts, ma’am.” –Joe Friday, Dragnet) Having trouble keeping up with DES and the recent stent studies? Want a brief tutorial? To learn the top six things every cardiologist should know about DES, read on… 1. What they do. DES are superior to both bare-metal stents and angioplasty in reducing the incidence […]

---

September 27th, 2010

Xience V Holds Its Own With Sirolimus-Eluting Stents

Larry Husten, PHD

In the trials presented on Thursday at TCT, the everolimus-eluting Xience V stent (EES) proved superior to the paclitaxel-eluting Taxus stent at 2 years. But, as Gregg Stone  discussed here recently, a more formidable comparator for EES are the sirolimus-eluting stents (SES). Two trials presented on Friday demonstrated that EES are comparable in efficacy to SES. […]

---

September 27th, 2010

Promising Results for New DES in Peripheral Disease

Larry Husten, PHD

A new drug-eluting stent designed to treat peripheral disease showed promising results in the largest trial yet of endovascular treatment in this population. The 12-month results of the Zilver PTX randomized trial comparing a novel paclitaxel-eluting stent versus balloon angioplasty and bare-metal stenting in patients with symptomatic above-the-knee femoropopliteal artery disease were presented at TCT2010 by Michael Dake. […]

---

September 24th, 2010

Xience V Stent Still Strong at 2 Years

Larry Husten, PHD

Two large trials presented at TCT continue to demonstrate the long-term superiority of the everolimus-eluting stent (EES) over the paclitaxel-eluting stent (PES). Gregg Stone presented two-year outcomes from more than 3500 patients randomized in the SPIRIT IV trial to either the Xience V or the Taxus stents. At two years, the rate of target lesion failure — defined […]

---